Abstract
Introduction Plasma amyloid-β (Aβ), phosphorylated tau (p-tau), and glial fibrillar acid protein (GFAP) can identify Alzheimer’s disease (AD) pathophysiology with high accuracy. However, comparing their performance in the same individuals remains under-explored.
Methods We compared the predictive performance of plasma Aβ42/40, p-tau(at threonine 181 and 231), neurofilament light (NfL), and GFAP to identify Aβ- and tau-PET positivity in 138 cognitive unimpaired (CU) and 87 cognitive impaired (CI) individuals.
Results In CU, plasma p-tau231 had the best performance to identify both Aβ- and tau-PET positivity. In CI, plasma GFAP showed the best predictive accuracy to identify both Aβ and tau-PET positivity.
Discussion Our results support plasma p-tau231 as a marker of early AD pathology and, that GFAP best identifies both PET Aβ and tau abnormalities in the brain of CI individuals. These findings highlight that the performance of blood-based protein biomarkers to identify the presence of AD pathophysiology is disease-stage dependent.
Competing Interest Statement
K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. S.G. has served as a scientific advisor to Cerveau Therapeutics. PCLF, CT, JPF-S, WSB, BB, DTL, JT, ALB, FZL, MC, GB, SS, JS, NR, VP, NMP, DLT, WEK, VLV, AC, ERZ, NJA, TKK, PR-N, TAP declare no competing interests.
Funding Statement
Al fundings are described in the main manuscript
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Douglas Mental Health University Institute Research Ethics Board and the Montreal Neurological Instituted PET working committee approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
